Evidence map›Paper›PMID 28976233›Full record

ReviewPrion2017

A review of drug therapy for sporadic fatal insomnia.

Pardis Tabaee Damavandi, Martin T Dove, Richard W Pickersgill

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Prion, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Insights into the Diagnosis, Treatment, and Management of Prion Diseases.CNS & neurological disorders drug targets · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Autonomic regulation during sleep and wakefulness: a review with implications for defining the pathophysiology of neurological disorders.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Pardis Tabaee Damavandia Queen Mary University of London , School of Biological and Chemical Sciences , London , UK.
Martin T Doveb Queen Mary University of London , School of Physics and Astronomy , London , UK.
Richard W Pickersgilla Queen Mary University of London , School of Biological and Chemical Sciences , London , UK.
Queen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSporadic fatal insomnia (sFI) is a rapid progressive neurodegenerative disease characterised by gradual to perpetual insomnia, followed by dysautonomia, coma and death.

methodsWe used Molecular Docking and Molecular Dynamics simulation methods, to study the toxic Fatal-Insomnia-prion conformations at local unfolding. The idea was to determine these sites and to stabilise these regions against unfolding and miss-folding, using a small ligand, based on a phenothiazine "moiety".

conclusionAs a result we here discuss current fatal insomnia therapy and present seven novel possible compounds for in vitro and in vivo screening.

Indexed as

Drug DesignAntipsychotic AgentsBrainChlorpromazineHumansInsomnia, Fatal FamilialMolecular Docking SimulationMolecular Dynamics SimulationMutationPhenothiazinesPrion ProteinsProtein UnfoldingAntipsychotic AgentsChlorpromazinePhenothiazinesPrion Proteinsdrug therapyFatal Familial Insomniaphenothiazinic derivativesprionsTSE

Identifiers

PMID28976233
PMCPMC5639864
OpenAlexW2761854663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.